By Daniella Parra
Sparrow Pharmaceuticals expanded its Phase 2 clinical trial for SPI-62 in combination with prednisolone to treat polymyalgia rheumatica (PMR), the company said.
The trial is exploring the potential benefits of SPI-62 in reducing the side effects of steroids like prednisolone, which often limit their effectiveness.
HSD-1 is an intracellular enzyme responsible for activating glucocorticoids, and its inhibition with SPI-62 could potentially mitigate the harmful effects of steroids in various tissues, such as the liver, adipose, muscle and skin, it said.
“We hypothesize that HSD-1 inhibition with SPI-62 can reduce the unwanted side effects of steroid medicines by lowering active steroid levels inside cells where steroids are known to cause toxicity,” said Dr. David Katz, Chief Scientific Officer of Sparrow. “Building upon the results seen in the first two cohorts, the third cohort is designed to expand our understanding of how to use SPI-62 in combination with prednisolone.”